RGNX
REGENXBIO Inc.
RGNX lost money over the past year, so it has no meaningful PE right now.
RGNX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Strong |
RGNX's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
RGNX PE Valuation
RGNX has no meaningful PE right now: it lost money over the past year.
RGNX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RGNX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
RGNX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.21 | +$0.24 |
| Q2 2026 | -$3.79 | -$0.37 |
| Q1 2026 | -$5.60 | -$2.51 |
| Q4 2025 | -$3.76 | +$0.83 |
| Q3 2025 | -$3.45 | +$1.57 |
| Q2 2025 | -$3.42 | +$1.84 |
| Q1 2025 | -$3.09 | +$2.78 |
| Q4 2024 | -$4.59 | +$1.43 |
RGNX is still losing money, but far less than before: $3.21 per share over the past year, against $6.50 at its worst in late 2022.
RGNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.2M | -69% |
| Q2 2026 | $108M | +406% |
| Q1 2026 | $6.4M | -93% |
| Q4 2025 | $30.3M | +43% |
| Q3 2025 | $29.7M | +23% |
| Q2 2025 | $21.4M | -4.2% |
| Q1 2025 | $89M | +470% |
| Q4 2024 | $21.2M | -4.5% |
RGNX's revenue has slid since its 2021 peak: $9M last quarter, down 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -388% | -212 points |
| Q2 2026 | 27% | +323 points |
| Q1 2026 | -1304% | -1318 points |
| Q4 2025 | -190% | +52 points |
| Q3 2025 | -176% | +80 points |
| Q2 2025 | -296% | -45 points |
| Q1 2025 | 14% | +422 points |
| Q4 2024 | -242% | +46 points |
RGNX's operating margin was −388% last quarter, down 212 points from the same quarter a year ago, near the bottom of its range since 2019.
RGNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.4M | +$94.9M |
| Q2 2026 | -$63M | -$13.3M |
| Q1 2026 | -$77.4M | -337% |
| Q4 2025 | -$52.8M | -$20.1M |
| Q3 2025 | -$56.5M | -$15.6M |
| Q2 2025 | -$49.7M | -$3.8M |
| Q1 2025 | $32.6M | +$88.6M |
| Q4 2024 | -$32.7M | +$9.2M |
RGNX has burned cash in almost every quarter: −$155M over the past year, against −$106M the year before.
RGNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +23% | +12.2M shares |
| 1 year | +26% | +13.6M shares |
| 3 years | +51% | +22.1M shares |
| 5 years | +76% | +28.2M shares |
RGNX has 65M diluted shares, up 26% from a year ago.
RGNX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -1.0x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -1.3x | Net Cash |
| Q4 2021 | -2.0x | Net Cash |
RGNX has more cash than debt.
RGNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.0 | Neutral |
| Stochastic | 20.6 | Neutral |
RGNX's weekly RSI is 47 (neutral) and its Stochastic is 21 (neutral).
RGNX PE vs Healthcare Sector
| Metric | RGNX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RGNX has no meaningful PE right now: it lost money over the past year.
RGNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.42 | 8.2% above |
| 20 week MA | $9.16 | 12% below |
| 50 week MA | $9.59 | 16% below |
| 100 week MA | $9.22 | 13% below |
| 200 week MA | $12.9 | 38% below |
RGNX has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 38% below its 200-week average.
RGNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.5 | $48.7 | +20% |
| 2021 | $48.7 | $34.8 | -29% |
| 2022 | $34.8 | $22.3 | -36% |
| 2023 | $22.3 | $18.0 | -19% |
| 2024 | $18.0 | $7.41 | -59% |
| 2025 | $7.41 | $14.2 | +91% |
| 2026 YTD | $14.2 | $8.03 | -43% |
RGNX has finished lower in four of the last six years. It's down 43% so far in 2026.